Posted by Michael Wonder on 04 Sep 2023
PHARMAC funds first treatment for primary progressive multiple sclerosis
4 September 2023 - PHARMAC has confirmed it is widening access to ocrelizumab (Ocrevus) as the first funded treatment for primary progressive multiple sclerosis.
In addition to widening access to ocrelizumab for primary progressive multiple sclerosis, PHARMAC is also confirming today that it is widening access to emicizumab for the treatment of severe haemophilia A. These changes will start from 1 October 2023.
